Biotechnology News and Research

RSS

SIGA completes fourth human clinical trial of ST-246 smallpox antiviral drug candidate

SIGA Technologies, Inc., a company specializing in the development of pharmaceutical agents to combat bio-warfare pathogens, announced today the successful completion of its fourth human clinical trial, supporting the safety and tolerability of the anticipated clinical dose of ST-246®, SIGA's lead smallpox antiviral drug candidate.

23 Jun 2010

Santaris Pharma, miRagen collaborate to develop microRNA-targeted medicines for cardiovascular disease

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies and miRagen Therapeutics, Inc., a biopharmaceutical company focused on developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, announced today that they have formed a strategic alliance to develop microRNA-targeted medicines for the treatment of cardiovascular disease.

23 Jun 2010

EUCODIS Bioscience launches high-performance beta-lactamase

EUCODIS Bioscience, a developer and manufacturer of customized enzymes today announced that it has launched a high-performance beta-lactamase designed to inactivate a broad range of beta-lactam antibiotics. EUCODIS Bioscience is marketing the product under the LacBuster(TM) brand.

23 Jun 2010

A*STAR physicist receives prestigious 2010 IEEE Medal for Innovations in Healthcare Technology

Physicist David William Townsend will be honoured with the prestigious 2010 IEEE Medal for Innovations in Healthcare Technology for the design, commercial development and clinical implementation of the PET/CT scanner. Prof Townsend will receive the medal jointly with his co-inventor, engineer Ronald Nutt, on 26 June 2010 at the IEEE Honors Ceremony in Montreal, Quebec, Canada. IEEE is the world's largest professional association advancing technology for humanity.

23 Jun 2010

MJFF supports Ceregene's CERE-120 Phase 2 study for PD with $2.5M award

The Michael J. Fox Foundation for Parkinson's Research (MJFF) will provide $2.5 million to support Ceregene Inc.'s new Phase 2 study of CERE-120. This novel gene therapy product delivers the gene for neurturin, a potent neurotrophic (growth) factor that has shown potential to improve the status of degenerating neurons in both preclinical and clinical studies. CERE-120 has the potential to improve motor function as well as slow Parkinson's disease (PD) progression.

23 Jun 2010

Understanding HIV viral protein structure could lead to new molecular medicines: Study

The UK's National Physical Laboratory is involved in a collaborative project that is helping to further the understanding of HIV viral protein structure which could lead to new molecular medicines.

23 Jun 2010

OvaGene Oncology opens new advanced molecular research and clinical laboratory facility

OvaGene Oncology Inc., a biotechnology company specializing in the development and commercialization of personalized DNA-based diagnostics for gynecologic cancer, announced today the opening of its new clinical and research laboratory in Irvine, California. This state-of-the-art facility will serve as the central headquarters for operations, research, and molecular clinical lab testing.

23 Jun 2010

TheraQuest launches new analgesic product pipeline

TheraQuest Biosciences, Inc., a clinical stage pain management company today unveiled its analgesic product pipeline. TheraQuest also announced the launch of its new corporate website at http://www.theraquestinc.com.

23 Jun 2010

Mice treated with XOMA 052 experiences improvement in measures associated with diabetes: Endocrinology

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced the publication of data from a mouse model of diet-induced obesity in the June, 2010 edition of the journal Endocrinology. The data showed that mice treated with XOMA 052 both prophylactically and therapeutically experienced improvement in measures associated with diabetes and cardiovascular disease including reduction in glycosylated hemoglobin levels, improvement in glucose control, improved beta-cell survival and function, and a reduction in total cholesterol without reduction in high density lipoprotein.

23 Jun 2010

IMUC signs exclusive licensing agreement with Targepeutics for acquisition of IL-13Ra2 receptor

ImmunoCellular Therapeutics, a clinical-stage biotechnology company focused on developing new immune-based products to treat cancer, today announced it has entered into an exclusive licensing agreement with Targepeutics, Inc. for ImmunoCellular's acquisition of Targepeutics' worldwide intellectual property rights surrounding the IL-13 receptor, alpha 2.

23 Jun 2010

FDA grants Tolera's TOL101 orphan drug designation for treatment of T1DM

Tolera Therapeutics, Inc., was granted orphan drug status by the United States Food and Drug Administration (FDA) for TOL101 (anti-TCR murine monoclonal antibody, type IgM), for treatment of recent onset immune-mediated Type 1 diabetes mellitus (T1DM). Designation is granted for treatment of patients sixteen years of age and younger with immune-mediated T1DM and preserved pancreatic beta-cell function, commonly referred to as juvenile diabetes.

23 Jun 2010

iCAD image analysis software program used in DCE-MRI studies demonstrated at ASCO 2010

ACR Image MetrixTM, an imaging contract research organization with expertise in imaging trial design, techniques and data extraction, in conjunction with its software partner, iCAD, gave demonstrations of the iCAD image analysis software program used in DCE-MRI studies at the ACR Image Metrix booth during the 2010 Annual American Society of Clinical Oncology Meeting, which took place June 4-8, 2010, in Chicago, IL.

23 Jun 2010

Genentech's Lucentis for treatment of macular edema following RVO receives FDA approval

Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has approved Lucentis® (ranibizumab injection) for the treatment of macular edema following retinal vein occlusion (RVO). The FDA approved this new indication after a six-month Priority Review.

23 Jun 2010

Neurologix announces positive results from Phase 2 trial of NLX-P101 for advanced PD

Neurologix, Inc., today announced positive results in a Phase 2 trial of its investigational gene therapy for advanced Parkinson's disease, NLX-P101. Study participants who received NLX-P101 experienced statistically significant and clinically meaningful improvements in off-medication motor scores compared to control subjects who received sham surgery.

22 Jun 2010

Three leading scientists gather to discuss Improved Strategies for Pre-clinical Cardiac Testing

Three leading scientists in the field of cardiac safety in pre-clinical drug development are gathering to discuss Improved Strategies for Pre-clinical Cardiac Testing in a free webinar on June 23 at 11:00 a.m. EDT, sponsored by the Drug Safety Council.

22 Jun 2010

New report measures growing adoption of centralized ECG services

ERT, a global provider of technology and services to the pharmaceutical, biotechnology and medical device industries, announced today the availability of a new report, conducted by the Tufts Center for the Study of Drug Development, mapping the growing adoption of centralized ECG (electrocardiogram) services. The industry-wide report measures the current and anticipated adoption levels of centralized ECGs in clinical trials.

22 Jun 2010

S1 registration statement of Kraig Biocraft Laboratories declared effective

Kraig Biocraft Laboratories, Inc., a biotechnology company focused on the development of commercially significant high performance polymers and technical fiber including spider silk, is very pleased to announce that its S1 registration statement has been declared effective. The Company filed the S1 registration statement in October of 2009 and has been working diligently over the last nine months to obtain this clearance.

22 Jun 2010

Biovest targets mantle cell lymphoma as next indication for BiovaxID

Biovest International, Inc. (Other OTC:BVTI) today announced at the Active Immunotherapeutics Forum in Barcelona, Spain, that the Company is targeting mantle cell lymphoma, in addition to follicular lymphoma, as a next indication for its personalized cancer vaccine, BiovaxID. At the conference, the Company reviewed positive data from an open label Phase II mantle cell lymphoma clinical trial and reported plans to meet with the FDA later this year to discuss a pathway to seek regulatory approval for this hematological indication for which there is no current consensus standard-of-care.

22 Jun 2010

TraceLink, Catalent announce partnership to improve production visibility for customers

TraceLink, Inc., the provider of the World's 1st Industry-Wide Supply Collaboration Network, and Catalent Pharma Solutions, Inc., a leading provider of innovative drug development and delivery solutions for pharmaceutical, biotechnology and consumer healthcare companies, today announced a partnership that will improve production visibility for Catalent customers across their entire manufacturing and packaging product lifecycle.

22 Jun 2010

QLT reports final 24-month results from Phase II RADICAL study in patients with wet AMD

QLT Inc. today announced final 24-month results from the Phase II RADICAL study (Reduced Fluence Visudyne Anti-VEGF-Dexamethasone In Combination for AMD Lesions) in patients with exudative (wet) age-related macular degeneration. The purpose of the study was to determine if Visudyne® combined with Lucentis® reduced retreatment rates compared with Lucentis monotherapy, while maintaining similar vision outcomes and an acceptable safety profile.

22 Jun 2010

Biotechnology News and Research

SIGA completes fourth human clinical trial of ST-246 smallpox antiviral drug candidate

Santaris Pharma, miRagen collaborate to develop microRNA-targeted medicines for cardiovascular disease

EUCODIS Bioscience launches high-performance beta-lactamase

A*STAR physicist receives prestigious 2010 IEEE Medal for Innovations in Healthcare Technology

MJFF supports Ceregene's CERE-120 Phase 2 study for PD with $2.5M award

Understanding HIV viral protein structure could lead to new molecular medicines: Study

OvaGene Oncology opens new advanced molecular research and clinical laboratory facility

TheraQuest launches new analgesic product pipeline

Mice treated with XOMA 052 experiences improvement in measures associated with diabetes: Endocrinology

IMUC signs exclusive licensing agreement with Targepeutics for acquisition of IL-13Ra2 receptor

FDA grants Tolera's TOL101 orphan drug designation for treatment of T1DM

iCAD image analysis software program used in DCE-MRI studies demonstrated at ASCO 2010

Genentech's Lucentis for treatment of macular edema following RVO receives FDA approval

Neurologix announces positive results from Phase 2 trial of NLX-P101 for advanced PD

Three leading scientists gather to discuss Improved Strategies for Pre-clinical Cardiac Testing

New report measures growing adoption of centralized ECG services

S1 registration statement of Kraig Biocraft Laboratories declared effective

Biovest targets mantle cell lymphoma as next indication for BiovaxID

TraceLink, Catalent announce partnership to improve production visibility for customers

QLT reports final 24-month results from Phase II RADICAL study in patients with wet AMD

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News